ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)
Japan · Delayed Price · Currency is JPY 2,930.00
+24.00 (0.83%)
May 29, 2026, 3:30 PM JST
TYO:4886 Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 6,991 | 6,192 | 9,862 | 5,357 | 6,163 |
Depreciation & Amortization | 3,085 | 2,247 | 2,662 | 3,127 | 2,885 |
Loss (Gain) From Sale of Assets | -90 | 300 | 2 | 6 | -3,466 |
Loss (Gain) From Sale of Investments | -1,230 | -127 | -3,340 | -124 | 1,151 |
Loss (Gain) on Equity Investments | 293 | 53 | 41 | 19 | -18 |
Other Operating Activities | 757 | -3,938 | -1,532 | -854 | -2,224 |
Change in Accounts Receivable | -867 | 1,203 | -370 | -742 | -1,361 |
Change in Inventory | -2,684 | -2,675 | -2,713 | -2,627 | -687 |
Change in Accounts Payable | -1,539 | 339 | 1,494 | -980 | 412 |
Change in Other Net Operating Assets | 1,587 | -1,109 | -4,620 | 169 | -13 |
Operating Cash Flow | 6,303 | 2,485 | 1,486 | 3,351 | 2,842 |
Operating Cash Flow Growth | 153.64% | 67.23% | -55.66% | 17.91% | -56.55% |
Capital Expenditures | -2,549 | -2,960 | -1,320 | -461 | -579 |
Sale of Property, Plant & Equipment | 166 | - | 1 | - | 10,312 |
Cash Acquisitions | -3,908 | -2,189 | -1,464 | - | -53 |
Divestitures | 47 | - | - | - | - |
Sale (Purchase) of Intangibles | -325 | -602 | -133 | -285 | -1,798 |
Investment in Securities | 1,716 | 752 | 3,778 | -210 | -45 |
Other Investing Activities | -899 | -1,125 | 844 | -170 | -1,094 |
Investing Cash Flow | -5,752 | -6,124 | 1,706 | -1,126 | 6,743 |
Long-Term Debt Issued | 3,500 | 3,000 | - | - | - |
Total Debt Issued | 3,500 | 3,000 | - | - | - |
Short-Term Debt Repaid | -738 | - | - | - | -50 |
Long-Term Debt Repaid | -1,937 | -4,680 | -3,138 | -1,423 | -2,298 |
Total Debt Repaid | -2,675 | -4,680 | -3,138 | -1,423 | -2,348 |
Net Debt Issued (Repaid) | 825 | -1,680 | -3,138 | -1,423 | -2,348 |
Repurchase of Common Stock | - | - | 9 | 55 | -248 |
Common Dividends Paid | -1,617 | -1,275 | -792 | -452 | -398 |
Other Financing Activities | -26 | -1 | -22 | - | -2 |
Financing Cash Flow | -818 | -2,956 | -3,943 | -1,820 | -2,996 |
Foreign Exchange Rate Adjustments | -208 | -97 | -15 | -2 | - |
Miscellaneous Cash Flow Adjustments | -1 | 556 | - | -1 | - |
Net Cash Flow | -476 | -6,136 | -766 | 402 | 6,589 |
Free Cash Flow | 3,754 | -475 | 166 | 2,890 | 2,263 |
Free Cash Flow Growth | - | - | -94.26% | 27.71% | -58.38% |
Free Cash Flow Margin | 5.28% | -0.74% | 0.26% | 4.78% | 4.00% |
Free Cash Flow Per Share | 132.26 | -16.76 | 5.86 | 102.34 | 79.77 |
Cash Interest Paid | 222 | 51 | 41 | 51 | 58 |
Cash Income Tax Paid | -756 | 4,026 | 1,611 | 850 | 1,385 |
Levered Free Cash Flow | 806.5 | -6,568 | 6,972 | 2,067 | 633.5 |
Unlevered Free Cash Flow | 945.25 | -6,536 | 6,997 | 2,098 | 668.5 |
Change in Working Capital | -3,503 | -2,242 | -6,209 | -4,180 | -1,649 |